Cargando…

An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)

SIMPLE SUMMARY: Microsatellite instability-high (MSI-H) is an established biomarker for response to immune checkpoint inhibitors (ICIs). ICIs are not usually administered in the first-line setting for MSI-H tumors including gastric cancer (GC), although such tumors tend to be less responsive to cyto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawakami, Hisato, Hironaka, Shuichi, Esaki, Taito, Chayama, Kazuaki, Tsuda, Masahiro, Sugimoto, Naotoshi, Kadowaki, Shigenori, Makiyama, Akitaka, Machida, Nozomu, Hirano, Hidekazu, Hirata, Kenro, Hara, Hiroki, Yabusaki, Hiroshi, Komatsu, Yoshito, Muro, Kei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918984/ https://www.ncbi.nlm.nih.gov/pubmed/33671871 http://dx.doi.org/10.3390/cancers13040805

Ejemplares similares

Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)
por: Takahashi, Naoki, et al.
Publicado: (2023)

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)
por: Okamoto, W., et al.
Publicado: (2022)

Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group
por: Hirata, Kenro, et al.
Publicado: (2020)

Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538
por: Klein, Oliver, et al.
Publicado: (2021)

Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial
por: Klein, Oliver, et al.
Publicado: (2021)

Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer
por: Muro, Kei, et al.
Publicado: (2023)

Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan
por: Aoki, Masahiko, et al.
Publicado: (2022)

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2018)

Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study
por: Shiroyama, Mamiko, et al.
Publicado: (2023)

Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study
por: Hosokawa, Ayumu, et al.
Publicado: (2020)

Phase I dose‐escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors
por: Esaki, Taito, et al.
Publicado: (2019)

MPS status report no. 209: Period 3.7.1972 - 5.8.1972
por: Frammery, B
Publicado: (1972)

Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032
por: Taylor, Matthew, et al.
Publicado: (2015)

Serum Insulin-Like Growth Factor Binding Protein 7 for Esophagogastric Junction Adenocarcinoma Diagnosis
por: Zhang, Gao-Ming, et al.
Publicado: (2020)

209 Fungal Sensitization and Its Relation to Asthma and Allergic Rhinitis in Children Aged 6 to 7 Years
por: Rodriguez, Alexander Diaz
Publicado: (2012)

At R209
por: CERN PhotoLab
Publicado: (1976)

At R209
Publicado: (1977)

At R209
Publicado: (1977)

At R209
Publicado: (1977)

At R209
Publicado: (1977)

At R209
Publicado: (1977)

At R209
por: CERN PhotoLab
Publicado: (1976)

A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy
por: Kumagai, Hozumi, et al.
Publicado: (2018)

Properties of $^{209}_{84}$Po$_{125}$ as observed in the decay of $^{209}$At
por: Alpsten, M, et al.
Publicado: (1971)

Comparison of the surgical treatment strategies for Siewert type II squamous cell carcinoma in the same area as esophagogastric junction carcinoma: data from a single Japanese high-volume cancer center
por: Yabusaki, Hiroshi, et al.
Publicado: (2013)

Ipilimumab
Publicado: (2012)

Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial
por: Doi, Toshihiko, et al.
Publicado: (2018)

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G
por: Shitara, Kohei, et al.
Publicado: (2016)

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
por: Boudadi, Karim, et al.
Publicado: (2018)

Letter of intent: investigation of the reaction $Bi^{209}$ ( p,p $pi^{+}$) $Pb^{209}$
por: Boos, Alexander H
Publicado: (1974)

R209 set-up
por: CERN PhotoLab
Publicado: (1976)

ISR experiment R 209
por: CERN PhotoLab
Publicado: (1979)

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study
por: André, Thierry, et al.
Publicado: (2023)

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
por: Yamamoto, Shun, et al.
Publicado: (2021)

Serum Insulin-Like Growth Factor Binding Protein 7 as a Potential Biomarker in the Diagnosis and Prognosis of Esophagogastric Junction Adenocarcinoma
por: Liu, Can-Tong, et al.
Publicado: (2020)

Search for the Higgs Boson in the Diphoton Channel with the ATLAS Detector using 209 pb-1 of 7 TeV Data taken in 2011
por: The ATLAS collaboration
Publicado: (2011)

Achieving sequential therapy in advanced gastric cancer: the importance of appropriate patient management for the elderly and/or those with ascites
por: Hamamoto, Yasuo, et al.
Publicado: (2020)

Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)
por: Tintelnot, Joseph, et al.
Publicado: (2020)

OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody
por: Ohmura, Hirofumi, et al.
Publicado: (2020)

Ipilimumab: Melanoma and beyond
por: Patel, Vishal, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_7mm88agvdvu2nkbj67rnbm7qtj